antidepressants/obesity

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT Not Applicable FIELD OF THE INVENTION The present invention relates to the treatment of obesity and the facilitation of weight loss by administration of a selective M.sub.1 muscarinic receptor (M.sub.1R)

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and .beta..sub.2 since 1967. Increased heart rate is the primary consequence of .beta..sub.1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from .beta..sub.2

RELATED APPLICATIONS This application claims priority to U.S. provisional application Ser. No. 60/006,070, filed Oct. 24, 1995, and to U.S. provisional application Ser. No. 60/004,332, filed Sep. 26, 1995. BACKGROUND OF THE INVENTION .beta.-Adrenoceptors have been subclassified as .beta..sub.1 and

BACKGROUND OF THE INVENTION This application is a divisional of application Ser. No. 10/131,987, filed on Apr. 25, 2002, now U.S. Pat. No. 6,525,075, filed on Feb. 25, 2003 which claims priority from provisional application Ser. No. 60/287,449, filed on Apr. 30, 2001, the entire disclosure of which

Major depressive disorder affects an estimated 340 million people worldwide. According to the World Health Organization, depression is the fourth greatest public health problem. If left untreated, the effects of depression can be devastating, robbing people of the energy or motivation to perform

BACKGROUND OF THE INVENTION Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%. Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the

BACKGROUND OF THE INVENTION Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%. Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the

BACKGROUND OF THE INVENTION Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%. Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the

BACKGROUND OF THE INVENTION Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15-20%. Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the

BACKGROUND OF THE INVENTION Major depression is a serious health problem affecting more than 5% of the population, with a life-time prevalence of 15 20%. Selective serotonin reuptake inhibitors have produced significant success in treating depression and related illnesses and have become among the